Helping you navigate through the maze of drug and device development.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
14. When to take an early FDA meeting, with Aleese Hopkins and Samira Shirwa
16:07
16:07
Spela senare
Spela senare
Listor
Gilla
Gillad
16:07
For smoother sailing with an IND, it can help to have a meeting with the FDA before the IND. But how do you do that and what do you need? Find out from Aleese Hopkins and Samira Shirwa.Av biologicsconsulting
…
continue reading
![Artwork](/static/images/128pixel.png)
1
13. Getting Out of Trouble, with Chris Vessely
18:10
18:10
Spela senare
Spela senare
Listor
Gilla
Gillad
18:10
When you have an anomalous lab result, you just might be in trouble. However, Chris Vessely can help you close the case of what went wrong, help you find a way to save the day, and help keep you from getting in trouble in the first place.Av biologicsconsulting
…
continue reading
![Artwork](/static/images/128pixel.png)
1
12. Cybersecurity for Medical Devices, With Becky Ditty and DonnaBea Tillman
27:28
27:28
Spela senare
Spela senare
Listor
Gilla
Gillad
27:28
Security from cyberattack for medical devices is paramount. And the FDA wants you to have a plan for it. Becky Ditty and Donna-Bea Tillman tell you how to be prepared. Guidance documents: Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions: Guidance for Industry and Food and Drug Administration Staff…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
11. eCTD 4.0 and standardized data, with Ben Wimmer
18:55
18:55
Spela senare
Spela senare
Listor
Gilla
Gillad
18:55
Changes are coming to regulatory submissions publishing and we talk about two of them, eCTD 4.0 and standardized data, with Ben Wimmer.Av biologicsconsulting
…
continue reading
![Artwork](/static/images/128pixel.png)
1
10. Commercial Readiness, with Vince Narbut
15:35
15:35
Spela senare
Spela senare
Listor
Gilla
Gillad
15:35
How prepared is your facility? Being prepared is crucial and in this episode Vince Narbut takes you through commercial readiness.Av biologicsconsulting
…
continue reading
![Artwork](/static/images/128pixel.png)
1
9. Weight of Evidence vs Carcinogenicity Testing Part 2, with Bruce Pearce
27:36
27:36
Spela senare
Spela senare
Listor
Gilla
Gillad
27:36
The ICH has released a guidance which may allow you to forego animal carcinogenicity testing in favor of a weight of the evidence argument. We conclude our two-part discussion of why to do that and how to do that with Bruce Pearce.Av biologicsconsulting
…
continue reading
![Artwork](/static/images/128pixel.png)
1
8. Weight of Evidence vs Carcinogenicity Testing Part 1, with Bruce Pearce
18:14
18:14
Spela senare
Spela senare
Listor
Gilla
Gillad
18:14
The ICH has released a guidance which may allow you to forego animal carcinogenicity testing in favor of a weight of the evidence argument. We begin our two-part discussion of why to do that and how to do that with Bruce Pearce.Av biologicsconsulting
…
continue reading
![Artwork](/static/images/128pixel.png)
1
7. Institutional Memory, with Kerin Ablashi
18:12
18:12
Spela senare
Spela senare
Listor
Gilla
Gillad
18:12
How can your organization continue to know what it's doing after people move on? Institutional memory. We talk about it with Kerin Ablashi.Av biologicsconsulting
…
continue reading
![Artwork](/static/images/128pixel.png)
1
6. Potency Assays, with Diana Colleluori
24:07
24:07
Spela senare
Spela senare
Listor
Gilla
Gillad
24:07
How well does it work and how can you illustrate that? Diana Colleluori explains potency assays and best practices with them.Av biologicsconsulting
…
continue reading
![Artwork](/static/images/128pixel.png)
1
5. When you should hire a consultant, with HeeSun Smaldore
15:53
15:53
Spela senare
Spela senare
Listor
Gilla
Gillad
15:53
HeeSun Smaldore discusses the intricacies of deciding when to hire an outside consultant.Av kkraihanzel
…
continue reading
![Artwork](/static/images/128pixel.png)
1
4. Assembling Your Non-Clinical IND, with Emily Noonan Place
15:22
15:22
Spela senare
Spela senare
Listor
Gilla
Gillad
15:22
The regulatory agency doesn't get a lot of time with your IND submission. To figure out how to make the most of that time, we talk with Emily Noonan Place.Av kkraihanzel
…
continue reading
![Artwork](/static/images/128pixel.png)
1
3. Gap analysis, with David Pepperl
21:19
21:19
Spela senare
Spela senare
Listor
Gilla
Gillad
21:19
You may not have everything that you need when it comes to making a drug or device submission. How do you know? With a gap analysis. David Pepperl explains it in our conversation.Av kkraihanzel
…
continue reading
![Artwork](/static/images/128pixel.png)
1
2. In vivo cell therapy, with Robert Kutner
20:44
20:44
Spela senare
Spela senare
Listor
Gilla
Gillad
20:44
Using your own cells to help you heal isn't science fiction anymore. Robert Kutner takes us into the world of in vivo cell therapy.Av kkraihanzel
…
continue reading
![Artwork](/static/images/128pixel.png)
1
1. What a consultant can do for you, with Debra Barngrover
13:20
13:20
Spela senare
Spela senare
Listor
Gilla
Gillad
13:20
Bringing a drug or device to market can be arduous. In this interview with Debra Barngrover of Biologics Consulting, we learn how a consultant can help bring your picture into focus. Guest: Debra Barngrover Host: James C. TaylorAv kkraihanzel
…
continue reading
A little bit about the show.Av kkraihanzel
…
continue reading